COVID-19 Vaccine Access in Asia Workshop

Chee Yoke Ling
Third World Network
16 – 18 August 2021


Profiteering from COVID-19 pandemic ... liability indemnity required

Pfizer


- 2021 Jan to March
 USD 3.5 billion revenue
 (25% of its total revenue)
- Forecast for 2021 revised from USD 15 billion to USD 26 billion (73% increase)
- Actual revenue expected to be more
- USD39 for 2 doses in the US & USD30 in the EU
- August 2021: EU price raised by 25% (from Euro 15.50 per dose to Euro 19.50) for new contract 2021-2023 → stocking for booster shots

Moderna

- Founded 11 years ago, never made profit, employed 830 prepandemic
- Expected sales in 2021:
 USD 18.4 billion
- Share price change on 12 months 2020/2021 + 372%
- USD 30 for 2 doses in the US and USD 36 in the EU
- August 2021: EU price raised by 10% (from USD 22.60 per dose to USD 25.50). Original price of USD 28.50 lowered because size of order has increased



Revenue forecast by vaccine type (\$bn)



Source: Airfinity

© FT

WTO Traderelated Aspects of Intellectual Property Rights Agreement (TRIPS)

- "Rights" to monopolies created by law:
 - 20 years minimum patents (products and processes/technology)
 - Undisclosed information (trade secrets) no time limit ("know-how")
 - Copyright –50 years plus lifetime of creator
- "TRIPS flexibilities" → exceptions, limits to monopoly, balancing beween private and public rights
- Voluntary licences from IP holders → failure for public health and access to affordable treatment
- From HIV to Hepatitis C to vaccines and more to come

The TRIPS Waiver

- 2 October 2020: India and South Africa joint submission TRIPS Waiver at the WTO TRIPS Council
- Temporary waiver of certain parts of TRIPS → WTO General Council consensus needed
- Global campaign of CSOs, patient groups, academia, parliamentarians (including European MPs), eminent persons, politifcal leaders, international organisations etc
- WHO Director General Dr. Tedros: "If not now, when?"
- Developing and least developed countries: 64 cosponsors and supporters and about another 40 supporters (18 August 2021)
- 5 May: the United States announced support for IPRs waiver for vaccines but not moving much
- European Union, UK and Switzerland continues to block negotiations
- STRONG OPPOSITION FROM BIG PHARMA

Revised Waiver Decision for negotiations (25 May 2021)

- 1. The obligations of Members to implement or apply Sections 1, 4, 5 and 7 of Part II of the TRIPS Agreement or to enforce these Sections under Part III of the TRIPS Agreement, shall be waived in relation to health products and technologies including diagnostics, therapeutics, vaccines, medical devices, personal protective equipment, their materials or components, and their methods and means of manufacture for the prevention, treatment or containment of COVID-19.
- → patents, undisclosed information (trade secrets), copyright, industrial design
- 2. This waiver shall be in force for **at least 3 years** from the date of this decision. The General Council shall, **thereafter**, **review** the existence of the exceptional circumstances justifying the waiver, and if such circumstances cease to exist, the General Council shall determine the date of termination of the waiver.

REMOVES LEGAL UNCERTAINTY AND PHARMA / RICH COUNTRY PRESSURES

64 Co-sponsors (25 May 2021 communication list PLUS Jordan on 6 Aug and Malaysia on 8 Aug) Another about 40 supporters



IP/C/W/669/Rev.1/Add.1

9 August 2021

(21-6131

Page: 1/1

Council for Trade-Related Aspects of Intellectual Property Rights

Original: English

WAIVER FROM CERTAIN PROVISIONS OF THE TRIPS AGREEMENT FOR THE PREVENTION,
CONTAINMENT AND TREATMENT OF COVID-19

REVISED DECISION TEXT

Addendum

By means of a communication dated 6 August 2021, the delegation of Jordan has requested to be added to the list of sponsors of the submission circulated in document IP/C/W/669/Rev.1.



IP/C/W/669/Rev.1/Add.2

9 August 2021

(21-6132)

Page: 1/1

Council for Trade-Related Aspects of Intellectual Property Rights

Original: English

WAIVER FROM CERTAIN PROVISIONS OF THE TRIPS AGREEMENT FOR THE PREVENTION, CONTAINMENT AND TREATMENT OF COVID-19

REVISED DECISION TEXT

Addendum

By means of a communication dated 8 August 2021, the delegation of Malaysia has requested to be added to the list of sponsors of the submission circulated in document IP/C/W/669/Rev.1.



IP/C/W/669/Rev.1

25 May 2021

(21-4307) Page: 1/4

Council for Trade-Related Aspects of Intellectual Property Rights

Original: English

WAIVER FROM CERTAIN PROVISIONS OF THE TRIPS AGREEMENT FOR THE PREVENTION, CONTAINMENT AND TREATMENT OF COVID-19

REVISED DECISION TEXT

COMMUNICATION FROM THE AFRICAN GROUP, THE PLURINATIONAL STATE OF BOLIVIA, EGYPT, ESWATINI, FIJI, INDIA, INDONESIA, KENYA, THE LDC GROUP, MALDIVES, MOZAMBIQUE, MONGOLIA, NAMIBIA, PAKISTAN, SOUTH AFRICA, VANUATU, THE BOLIVARIAN REPUBLIC OF VENEZUELA AND ZIMBABWE

By means of a communication dated 21 May 2021, the following document is circulated at the request of the delegations of the African Group, the Plurinational State of Bolivia, Egypt, Eswatini, Fiji, India, Indonesia, Kenya, the LDC Group, Maldives, Mozambique, Mongolia, Namibia, Pakistan, South Africa, Vanuatu, the Bolivarian Republic of Venezuela and Zimbabwe.

Asian co-sponsors of the TRIPS
Waiver (as of 18
August 2021)

India

Bangladesh, Cambodia, Lao, Myanmar → through the Least Developed Country (LDC) Group

Pakistan

Indonesia

Malaysia

Some materials on the TRIPS Waiver:

Compilation of selected WTO documents, reports on TRIPS Council, campaign statements and reports

https://twn.my/title2/intellectual property/trips waiver proposal.htm

MSF Access Campaign

https://msfaccess.org/

Feminists for a People's Vaccine

https://feminists4peoplesvaccine.org/



Changing the rules on intellectual property?